Switzerland
  • Switzerland
  • USA
  • confinis ag, Hauptstrasse 16, CH-3186 Düdingen, Switzerland
  • info.ch@confinis.com
  • +41 26 494 8 494
  • confinis corp., 4445 Willard Ave, Suite 600, Chevy Chase, MD 20815, USA
  • info.usa@confinis.com
  • +1 240 252 0891
confinis
confinis
  • Home
  • About
  • Services
    • Combination Products
    • In-Vitro Diagnostics
    • Product Development
    • QM, Auditing & Training
    • Regulatory Affairs
  • Blog
  • Join
    • Careers
    • Independent professional
  • Contact
    • Offices
    • Newsletter
    • Disclaimer
    • Cookie Policy
   
  • How does the notified body assess your clinical evaluation?
    February 18, 2021
  • How to perform a clinical evaluation for Medical Device Software
    January 28, 2021
  • How to ensure sufficient clinical evidence for legacy devices
    January 15, 2021
  • How to claim an equivalence in the clinical evaluation under the MDR
    December 21, 2020
  • Novelties for Clinical Evaluation and Post Market Surveillance within MDR – the Posts Series
    December 10, 2020
  • Bei Medizinprodukten auf die EU warten hilft der Schweiz wenig
    December 3, 2020
  • Workplace glasses
    Revision der Schweizer Medizinprodukteverordnung mit Folgen
    August 14, 2020
  • Interpellation Jacqueline de Quattro on medical devices
    June 2, 2020
  • Politics intervene regarding medical devices
    May 8, 2020
  • Notifiedbody audits
    EU MDR audit requirements and links to MDSAP program
    February 14, 2019
  • 1
  • 2
  • 3
The confinis Blog

Welcome to the confinis blog. This is the place where we are writing about news, events and helpful information. Enjoy.

Archives
Categories
  • Conferences
  • confinis
  • Regulations
  • Workshops
Tags
#2017/745 #CHREP #FDA #machinelearning 2018 BLA clinicalevaluation combination products confinis digitalhealth EMC howto IEC60601 IEC80601 InstA ISO13485 IVD ivdr MDCG mdr mdr article 117 MedDO medicaldevices medicalsoftware medizinprodukte Medizinprodukteverordnung MepV mhra motivation MRA OBDS peter studer PMS post-market-clinical-follow-up post-market-surveillance presentation qms regulations samd startup swiss-medtech switzerland TOPRA ukrp workshop

Combination Products Services

  • MDR Article 117
  • Combination Products
  • Design Control
  • Risk Management
  • Usability Engineering
  • Clinical Evaluation
  • 21 CFR Part 4

In-Vitro Diagnostics

  • New IVDR
  • Classification and Regulatory Strategy
  • CE marking, FDA and global product registrations
  • Performance Evaluation
  • Software

Product Development Services

  • Digital Health
  • Design Control
  • Risk Management
  • Usability Engineering
  • Clinical Evaluation
  • Regulatory Due Diligence
  • Combination Products
  • DHF Remediation
  • Software Validation
  • Mobile Medical Apps
  • Production & Process Optimization
  • Packaging

QM, Auditing & Training Services

  • eQMS
  • Quality Management System
  • Design Control
  • Training
  • Auditing
  • Validation / Qualification
  • FDA Inspections
  • Postmarket Surveillance

Regulatory Affairs & Market Authorization

  • Digital Health
  • Regulatory Affairs Strategy
  • Market Authorization in Europe
  • Market Authorization in the USA
  • Market Authorization in other Markets
  • EC Representative
  • US Agent
RAPS - Enterprise Member Logo
© 2023 confinis ag. All rights reserved. Disclaimer & Cookie Policy. Website: SENF Digital Graphics: zwo13